Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical update

Table 2 Frequency of gastrointestinal toxicities in metastatic colorectal cancer: results from main recent clinical trials

Trials	Nausea		Vomiting		Diarrhea		Oral mucositis
	Any grade	G3-G4	Any grade	G3-G4	Any grade	G3-G4	Any grade	G3-G4
Folfiri + cetuximab (FIRE-3 trial, Heinemann et al[12]. Lancet Oncol 2014)	45%	3%	22%	2%	46%	11%	38%	4%
Folfiri + bevacizumab (FIRE-3 trial, Heinemann et al[12]. Lancet Oncol 2014)	58%	5%	29%	3%	49%	12%	41%	3%
Folfiri + aflibercept (VELOUR trial, Van Cutsem et al[60]. J Clin Oncol 2012)	53.4%	1.8%	32.9%	2.8%	69.2%	19.3%	54.8%	13.8%
Regorafenib (CORRECT trial, Grothey et al[63]. Lancet 2013)	14%	< 1%	8%	1%	34%	7%	27%	3%
Folfoxiri + bevacizumab (Tribe trial, Loupakis et al[13]. N Engl J Med 2014)		2.8%		4.4%		18.8%		8.8%
Folfox + bevacizumab (Tribe trial, Loupakis et al[13]. N Engl J Med 2014)		3.2%		3.2%		10.6%		4.3%